Walnut Creek, CA—Dark Horse Consulting (DHC) today announces the make-up of its Board of Directors.
Dark Horse Consulting, the rapidly growing global consulting practice specializing exclusively in cell and gene therapies, understands the challenges specific to C> sponsors, tool providers, and investors. 2020 was another banner year for financing in cell and gene therapy and Dark Horse’s Board of Directors is positioned to consider the resultant therapeutic, developmental, and financial implications.
To quote Anthony Davies, DHC Founder, CEO, and Board Chair, “Our board is composed of individuals with innovative biotech and investor expertise, providing us the necessary positioning and leadership to ensure that the service we provide to our clients remains second-to-none. Katy Spink and I are pleased with the resourcefulness and ingenuity—both in strategic and operational capacities—represented within this Board of Directors.”
The Dark Horse Consulting Board of Directors comprises:
CEO and Board Chair Anthony Davies, Ph.D., who founded Dark Horse Consulting (DHC) in 2014 as the first—and to date, only—consulting practice exclusively focused on Cell and Gene Therapy. Since then, the global team assembled under his leadership has provided services to numerous clients worldwide. Anthony is known for his considered and sometimes provocative thought-leadership in the space. Before founding Dark Horse, Dr. Davies served as a senior executive for multiple publicly traded and privately held companies, building a reputation of innovation, dedication, and competency.
Dark Horse COO, Managing Partner, and Board Director Katharine (Katy) Spink, Ph.D., who combines nearly two decades of C> operating experience with strategic vision and a well-deserved reputation as an incisive analytical mind. Cross-functional leadership experience across the technical foundations of C> makes Katy effective in providing expert guidance in integration and overlap of all industry needs. Dr. Spink’s pre-Dark Horse experience included management consulting with McKinsey & Company as well as executive roles in the field of Cell & Gene Therapy.
Board Director Rajeev Amara, Chief Executive Officer of Arcline Investment Management, with whom Dark Horse entered a strategic partnership in July of 2019. Amara, a University of Pennsylvania graduate, founded the private equity firm Arcline in 2018 to focus on growth oriented buyouts in the biopharma, medical technology and specialty industrial sectors. Prior to Arcline, Amara spent nearly two decades at the private equity firm Golden Gate Capital, where he led 15 investments in a variety of industries including life sciences and healthcare. Arcline currently manages over $4.2 billion of committed capital, with significant investments in the cell and gene therapy space.
Board Director David Greenwood, currently serving as either Board Director or Advisor to several private companies. Between 1995 and December of 2011, Mr. Greenwood served as Chief Financial Officer and Chief Executive Officer of Geron Corporation, a biotechnology company in the fields of regenerative medicine and cancer. From 1979 to 1995, he held a series of senior positions with JPMorgan, an international banking firm. Mr. Greenwood, who holds an MBA from Harvard Business School, is known for his thought-leadership on biotech financing.
Board Director Ronald Park, a physician with extensive experience in multiple biopharma functions, including drug pricing and reimbursement. A McKinsey & Company alumnus and Stanford MD/MBA, Dr. Park spent sixteen years in various leadership roles at Roche and Genentech, before joining Ancestry as EVP of Health and DNA in 2020. While at Roche/Genentech, Ron co-founded and co-led Roche Personalized Healthcare Center of Excellence, leading the company’s efforts to globally accelerate the use of genomics, real-world data, and digital health for the development and delivery of medicines to patients with serious diseases.
About Dark Horse Consulting Group
Dark Horse Consulting—a global company with offices in both California and London—specializes in the development of Cell and Gene Therapy products. DHC’s collective knowledge spans manufacturing support, process development and comparability, analytical development, quantitative modeling, quality systems, device development, regulatory support, project and program management, market research, intellectual property, and financing and diligence. Dark Horse offers an unmatched understanding of the challenges faced by cell and gene therapy developers and is able to apply best practices from this and other industries to address a diverse range of client needs.